| Sign In to gain access to subscriptions and/or personal tools. |
Benefit Coverage of Novel Antipsychotics in Medicaid Programs and the Veterans Health AdministrationDepartment of Veterans Affairs, South Central Mental Illness Research, Education, and Clinical Center (MI-RECC), Little Rock, Ark and Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, Ark, gsullivan{at}uams.edu
Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, Ark
Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, Ark
Division of Medicaid, State of Mississippi When risperidone, olanzapine, and quetiapine were introduced, concerns were raised regarding the extent to which drug benefit policies might constrain their use. A national survey of eligible Medicaid programs (N = 47; 100%) and Veterans Health Administration facilities (N = 141; 94%) in 1998 found that within Medicaid, open formularies were common, preauthorization requirements were rare, and few barriers existed, whereas VHA facilities reported relatively more constraints in terms of formulary restrictions and preauthorization requirements. Although drug benefit policies have the potential to exert a major influence over prescribing practices, it is unlikely that these policies significantly restricted access to these antipsychotics.
Key Words: Medicaid • novel antipsychotics • prescribing practices • Veterans Health Administration
American Journal of Medical Quality, Vol. 19, No. 1,
37-40 (2004) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
